Literature DB >> 15695376

Cellular targets of gefitinib.

Dirk Brehmer1, Zoltán Greff, Klaus Godl, Stephanie Blencke, Alexander Kurtenbach, Martina Weber, Stefan Müller, Bert Klebl, Matt Cotten, György Kéri, Josef Wissing, Henrik Daub.   

Abstract

Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear. Here, we used a proteomic method to profile the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest alternative cellular modes of action for gefitinib and provide rationales for the development of related drugs.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15695376

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  76 in total

1.  Integrating molecular diagnostics into anticancer drug discovery.

Authors:  István Peták; Richárd Schwab; László Orfi; László Kopper; György Kéri
Journal:  Nat Rev Drug Discov       Date:  2010-06-07       Impact factor: 84.694

2.  Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines.

Authors:  Romel Somwar; Hediye Erdjument-Bromage; Erik Larsson; David Shum; William W Lockwood; Guangli Yang; Chris Sander; Ouathek Ouerfelli; Paul J Tempst; Hakim Djaballah; Harold E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

Review 3.  The role of targeted chemical proteomics in pharmacology.

Authors:  Chris W Sutton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Cardioproteomics: advancing the discovery of signaling mechanisms involved in cardiovascular diseases.

Authors:  Ziyou Cui; Shannamar Dewey; Aldrin V Gomes
Journal:  Am J Cardiovasc Dis       Date:  2011-09-10

5.  Protein kinase affinity reagents based on a 5-aminoindazole scaffold.

Authors:  Ratika Krishnamurty; Amanda M Brock; Dustin J Maly
Journal:  Bioorg Med Chem Lett       Date:  2010-10-21       Impact factor: 2.823

6.  Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.

Authors:  Fumiyuki Yamasaki; Dongwei Zhang; Chandra Bartholomeusz; Tamotsu Sudo; Gabriel N Hortobagyi; Kaoru Kurisu; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2007-08-01       Impact factor: 6.261

7.  Large-scale proteomics analysis of the human kinome.

Authors:  Felix S Oppermann; Florian Gnad; Jesper V Olsen; Renate Hornberger; Zoltán Greff; György Kéri; Matthias Mann; Henrik Daub
Journal:  Mol Cell Proteomics       Date:  2009-04-15       Impact factor: 5.911

Review 8.  Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.

Authors:  Déborah Tribouillard; Fabienne Gug; Hervé Galons; Stéphane Bach; Sven J Saupe; Marc Blondel
Journal:  Prion       Date:  2007-01-20       Impact factor: 3.931

9.  Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression.

Authors:  Kalyan Dulla; Henrik Daub; Renate Hornberger; Erich A Nigg; Roman Körner
Journal:  Mol Cell Proteomics       Date:  2010-01-23       Impact factor: 5.911

10.  Quantitative phosphokinome analysis of the Met pathway activated by the invasin internalin B from Listeria monocytogenes.

Authors:  Tobias Reinl; Manfred Nimtz; Claudia Hundertmark; Thorsten Johl; György Kéri; Jürgen Wehland; Henrik Daub; Lothar Jänsch
Journal:  Mol Cell Proteomics       Date:  2009-07-29       Impact factor: 5.911
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.